MA32828B1 - Composes qui favorisent le developpement de cellules souches hematopoietiques - Google Patents

Composes qui favorisent le developpement de cellules souches hematopoietiques

Info

Publication number
MA32828B1
MA32828B1 MA33889A MA33889A MA32828B1 MA 32828 B1 MA32828 B1 MA 32828B1 MA 33889 A MA33889 A MA 33889A MA 33889 A MA33889 A MA 33889A MA 32828 B1 MA32828 B1 MA 32828B1
Authority
MA
Morocco
Prior art keywords
stem cells
hematopoietic stem
compounds
promote
development
Prior art date
Application number
MA33889A
Other languages
Arabic (ar)
English (en)
Inventor
Anthony Boitano
Michael Cooke
Shifeng Pan
Peter G Schultz
John TELLEW
Yongqin Wan
Xing Wang
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42111339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32828(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc filed Critical Irm Llc
Publication of MA32828B1 publication Critical patent/MA32828B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRÉSENTE INVENTION PORTE SUR DES COMPOSÉS ET DES COMPOSITIONS POUR DÉVELOPPER LE NOMBRE DE LYMPHOCYTES CD34+ POUR UNE TRANSPLANTATION. L'INVENTION PORTE EN OUTRE SUR UNE POPULATION CELLULAIRE COMPRENANT DES CELLULES SOUCHES HÉMATOPOÏÉTIQUES DÉVELOPPÉES (HSC) ET SUR SON UTILISATION DANS UNE TRANSPLANTATION AUTOLOGUE OU ALLOGÈNE POUR LE TRAITEMENT DE PATIENTS AVEC DES MALADIES D'IMMUNODÉFICIENCE ET DES MALADIES AUTO-IMMUNES HÉRÉDITAIRES ET DIVERS TROUBLES HÉMATOPOÏÉTIQUES POUR RECONSTITUER LES LIGNÉES DE CELLULES HÉMATOPOÏÉTIQUES ET LA DÉFENSE DU SYSTÈME IMMUNITAIRE.
MA33889A 2008-10-30 2011-05-25 Composes qui favorisent le developpement de cellules souches hematopoietiques MA32828B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10982108P 2008-10-30 2008-10-30
US24276509P 2009-09-15 2009-09-15
PCT/US2009/062646 WO2010059401A2 (fr) 2008-10-30 2009-10-29 Composés qui favorisent le développement de cellules souches hématopoïétiques

Publications (1)

Publication Number Publication Date
MA32828B1 true MA32828B1 (fr) 2011-11-01

Family

ID=42111339

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33889A MA32828B1 (fr) 2008-10-30 2011-05-25 Composes qui favorisent le developpement de cellules souches hematopoietiques

Country Status (41)

Country Link
US (4) US8927281B2 (fr)
EP (2) EP3524604B1 (fr)
JP (1) JP5390626B2 (fr)
KR (1) KR101434719B1 (fr)
CN (1) CN102203096B (fr)
AR (1) AR074063A1 (fr)
AU (1) AU2009317898B2 (fr)
BR (1) BRPI0921799B8 (fr)
CA (3) CA2943540C (fr)
CL (2) CL2009002010A1 (fr)
CO (1) CO6410309A2 (fr)
CR (1) CR20110192A (fr)
CU (1) CU24495B1 (fr)
CY (1) CY1121857T1 (fr)
DK (1) DK2350078T3 (fr)
DO (1) DOP2011000114A (fr)
EA (1) EA019872B1 (fr)
EC (1) ECSP11011090A (fr)
ES (2) ES2736728T3 (fr)
GE (1) GEP20146053B (fr)
HN (1) HN2011001195A (fr)
HR (1) HRP20191238T1 (fr)
HU (1) HUE044802T2 (fr)
IL (1) IL212368A (fr)
JO (1) JO3593B1 (fr)
LT (1) LT2350078T (fr)
MA (1) MA32828B1 (fr)
MX (1) MX347834B (fr)
MY (1) MY155137A (fr)
NI (1) NI201100083A (fr)
NZ (1) NZ592435A (fr)
PE (1) PE20100362A1 (fr)
PL (1) PL2350078T3 (fr)
PT (1) PT2350078T (fr)
RS (1) RS59027B1 (fr)
SI (1) SI2350078T1 (fr)
SM (1) SMP201100024B (fr)
SV (1) SV2011003888A (fr)
TN (1) TN2011000174A1 (fr)
TW (1) TWI532486B (fr)
WO (1) WO2010059401A2 (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846393B2 (en) * 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
KR101564233B1 (ko) * 2007-03-28 2015-10-29 뉴로서치 에이/에스 푸리닐 유도체 및 칼륨 채널 조절제로서의 이의 용도
EP2144911A2 (fr) * 2007-03-28 2010-01-20 NeuroSearch AS Dérivés de purinyle et leur utilisation en tant que modulateurs des canaux potassiques
CA2721851A1 (fr) * 2008-05-30 2009-12-03 Genentech, Inc. Composes inhibiteurs de la pi3k de type purine et procedes d'utilisation
US8268838B2 (en) * 2008-09-26 2012-09-18 Neurosearch A/S Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators
US20110237607A1 (en) * 2008-09-26 2011-09-29 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
WO2012074068A1 (fr) * 2010-12-01 2012-06-07 日産化学工業株式会社 Procédé de production de cellules souches hématopoïétiques à l'aide d'un composé pyrazole
WO2012102937A2 (fr) * 2011-01-25 2012-08-02 Irm Llc Composés qui développent des cellules souches hématopoïétiques
WO2012167053A1 (fr) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Nouveaux modulateurs du système immunitaire
WO2013006806A1 (fr) * 2011-07-06 2013-01-10 Cellerant Therapeutics, Inc. Cellules progénitrices mégacaryocytaires pour la production de plaquettes
EP2739735A2 (fr) * 2011-08-01 2014-06-11 Alnylam Pharmaceuticals, Inc. Procédé permettant d'améliorer le taux de succès des greffes de cellules souches hématopoïétiques
US9593062B2 (en) * 2011-09-07 2017-03-14 Deutschland Krebsforschungszentrum Means and methods for treating and/or preventing natural AHR ligand-dependent cancer
EP2788476B1 (fr) * 2011-12-08 2019-05-22 Fred Hutchinson Cancer Research Center Compositions et procédés pour la génération améliorée de cellules souches/progénitrices hématopoïétiques
EP2807165B1 (fr) 2012-01-27 2019-05-15 Université de Montréal Dérivés de pyrimido[4,5-b]indole et leur utilisation dans l'expansion des cellules souches hématopoïétiques
HK1202581A1 (en) 2012-02-13 2015-10-02 Gamida-Cell Ltd. Mesenchymal stem cells conditioned medium and methods of generating and using the same
US9475797B2 (en) 2012-06-26 2016-10-25 Saniona A/S Phenyl triazole derivative and its use for modulating the GABAA receptor complex
US9567569B2 (en) * 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
EP2943566A1 (fr) 2013-01-08 2015-11-18 Fred Hutchinson Cancer Research Center Compositions et procédés pour l'expansion de cellules souches hématopoïétiques embryonnaires
WO2014138485A1 (fr) 2013-03-08 2014-09-12 Irm Llc Production de plaquettes ex vivo à partir de cellules souches hématopoïétiques et leur produit
US9757378B2 (en) * 2013-05-17 2017-09-12 Universite De Montreal Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation
EP3060670B1 (fr) * 2013-10-24 2019-07-10 Ospedale San Raffaele S.r.l. Méthode
CN105873952A (zh) 2013-10-31 2016-08-17 弗莱德哈钦森癌症研究中心 经修饰的造血干细胞/祖细胞和非t效应细胞及其用途
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2016118780A1 (fr) 2015-01-21 2016-07-28 Fred Hutchinson Cancer Research Center Plate-forme point-of-care et/ou portative pour thérapie génique
EP3288570A4 (fr) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Cellules souches modifiées et leurs utilisations
EP3288569A4 (fr) 2015-04-29 2018-12-19 Fred Hutchinson Cancer Research Center Cellules souches/progénitrices hématopoïétiques et effectrices non t modifiées, et leurs utilisations
EA201890960A1 (ru) * 2015-10-15 2018-10-31 Селулэрити, Инк. Натуральные киллеры и клетки ilc3 и их применение
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
SG11201803419PA (en) 2015-10-30 2018-05-30 The Regents Of The Universtiy Of California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
MX2018007987A (es) * 2015-12-28 2019-01-10 Novartis Ag Composiciones y metodos para el tratamiento de hemoglobinopatias.
EP4711465A2 (fr) 2016-04-14 2026-03-18 Fred Hutchinson Cancer Center Compositions et procédés pour programmer des cellules thérapeutiques à l'aide de nanovecteurs d'acide nucléique ciblés
BR112018072701A2 (pt) * 2016-05-07 2019-02-19 Celularity, Inc. métodos de tratamento de leucemia mieloide aguda e mieloma múltiplo usando células exterminadoras naturais
AU2017269870A1 (en) 2016-05-25 2018-12-06 Bayer Pharma Aktiengesellschaft 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
SG11201901199WA (en) * 2016-08-18 2019-03-28 Nat Univ Singapore Substituted azole derivatives for generation, proliferation and differentiation of hematopoietic stem and progenitor cells
CN109844126A (zh) 2016-09-28 2019-06-04 诺华股份有限公司 基于多孔膜的大分子递送系统
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
HUE053191T2 (hu) 2017-02-09 2021-06-28 Bayer Ag 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
TW201841916A (zh) * 2017-04-12 2018-12-01 美商麥珍塔治療學股份有限公司 芳香烴受體拮抗劑及其用途
MX2019012431A (es) * 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
JP7538601B2 (ja) 2017-04-26 2024-08-22 ユーリカ セラピューティックス， インコーポレイテッド キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用
US11548867B2 (en) 2017-07-19 2023-01-10 Idea Ya Biosciences, Inc. Amido compounds as AhR modulators
EP3661500B1 (fr) 2017-07-31 2026-01-07 Novartis AG Utilisation de mavoglurant dans la réduction de l'utilisation de cocaïne ou dans la prévention d'une rechute dans l'utilisation de cocaïne
WO2019027765A1 (fr) * 2017-08-02 2019-02-07 Northwestern University Composés de pyrimidine fusionnés substitués et leurs utilisations
WO2019067792A1 (fr) 2017-09-28 2019-04-04 Celularity, Inc. Suppression de tumeur à l'aide de cellules tueuses naturelles intermédiaires dérivées du placenta humain (pink) en combinaison avec un anticorps
KR102832035B1 (ko) 2017-09-29 2025-07-09 인텔리아 테라퓨틱스, 인크. 지질 나노파티클을 이용한 mRNA 전달의 체외 방법
US20190314407A1 (en) 2017-10-31 2019-10-17 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
EP3703715A1 (fr) 2017-10-31 2020-09-09 Magenta Therapeutics, Inc. Compositions et procédés de greffe de cellules souches hématopoïétiques
EP3713923B1 (fr) 2017-11-21 2021-12-01 Bayer Aktiengesellschaft 2-phénylpyrimidine-4-carboxamides à utiliser en tant qu'inhibiteurs d'ahr
EP3713926B1 (fr) 2017-11-21 2023-06-07 Bayer Aktiengesellschaft 4-carboxamides de 2-hetarylpyrimidine comme des antagonistes de l'aryl hydrocarbon receptor
CA3082857A1 (fr) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
CA3082856A1 (fr) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 3-oxo-2,3-dihydropyridazine-4-carboxamides substitues par du soufre
CN111712262A (zh) 2017-12-06 2020-09-25 美真达治疗公司 用于动员造血干细胞和祖细胞的给药方案
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US20200338132A1 (en) * 2018-01-03 2020-10-29 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
WO2019156989A1 (fr) * 2018-02-06 2019-08-15 Ideaya Biosciences, Inc. Composés et procédés pour la modulation d'ahr
US20220340875A1 (en) * 2018-07-19 2022-10-27 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using amido compounds
WO2020039093A1 (fr) 2018-08-24 2020-02-27 Jaguahr Therapeutics Pte Ltd Dérivés de tétrahydropyridopyrimidine utilisés comme modulateurs du ahr
EP3843853A1 (fr) 2018-08-31 2021-07-07 Jaguahr Therapeutics Pte Ltd Composés hétérocycliques en tant que modulateurs de l'ahr
WO2020050409A1 (fr) 2018-09-07 2020-03-12 Otsuka Pharmaceutical Co., Ltd. Composé hétérocyclique
WO2020056170A1 (fr) 2018-09-12 2020-03-19 Fred Hutchinson Cancer Research Center Réduction de l'expression de cd33 pour protéger sélectivement des cellules thérapeutiques
EP3867253A4 (fr) * 2018-10-16 2022-05-18 Ikena Oncology, Inc. Inhibiteurs d'indole ahr et leurs utilisations
CN113302287A (zh) * 2018-10-31 2021-08-24 美真达治疗公司 用于造血干细胞和祖细胞移植疗法的方法
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
WO2021028382A1 (fr) 2019-08-12 2021-02-18 Bayer Aktiengesellschaft [1,2,4]triazolo[1,5-c]quinazolin-5-amines
EP4051298A1 (fr) 2019-11-01 2022-09-07 Magenta Therapeutics, Inc. Schémas posologiques pour la mobilisation de cellules souches et progénitrices hématopoïétiques
AU2020394424A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
IL291322B2 (en) * 2019-12-09 2026-02-01 Otsuka Pharma Co Ltd Acrylamide compounds
JP7846007B2 (ja) 2019-12-18 2026-04-14 ノバルティス アーゲー 異常ヘモグロビン症の治療用組成物及び方法
JP2023515128A (ja) 2020-02-26 2023-04-12 ジャガー セラピューティクス ピーティーイーリミテッド Ａｈｒシグナル伝達の調節に有用なピリドピリミジン誘導体
EP4146797A1 (fr) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Traitement pour les maladies neurodégénératives
EP4146284A1 (fr) 2020-05-06 2023-03-15 Cellectis S.A. Procédés de modification génétique de cellules pour l'administration de protéines thérapeutiques
CN115803435A (zh) 2020-05-06 2023-03-14 塞勒克提斯公司 用于在细胞基因组中靶向插入外源序列的方法
KR20230034299A (ko) 2020-07-01 2023-03-09 네쿠스젠 가부시키가이샤 인간 장기 조혈 간세포 마커
WO2022029063A1 (fr) 2020-08-04 2022-02-10 Bayer Aktiengesellschaft Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines
CN114369097B (zh) * 2020-10-15 2023-07-14 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
WO2022197776A1 (fr) 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Schémas posologiques pour la mobilisation des cellules souches hématopoïétiques en vue d'une greffe de cellules souches chez les patients atteints de myélome multiple
US20250127809A1 (en) 2021-06-23 2025-04-24 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
US20250135039A1 (en) 2022-02-07 2025-05-01 Ensoma, Inc. Inhibitor-resistant mgmt modifications and modification of mgmt-encoding nucleic acids
US12191004B2 (en) 2022-06-27 2025-01-07 Microsoft Technology Licensing, Llc Machine learning system with two encoder towers for semantic matching
TW202413646A (zh) 2022-07-22 2024-04-01 美商萊爾免疫藥物股份有限公司 免疫細胞療法
CN119948035A (zh) 2022-10-03 2025-05-06 捷豹治疗有限公司 可用于调节AhR信号传导的化合物

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3399196A (en) 1959-01-22 1968-08-27 Ciba Geigy Corp Nu-substituted pyrazolo-pyrimidines
DE3150486A1 (de) * 1981-12-19 1983-08-25 Merck Patent Gmbh, 6100 Darmstadt Imidazo(4,5-c)pyridine, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
US5437994A (en) * 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5117830A (en) 1990-11-08 1992-06-02 Whitby Research, Inc. Method of determining viability of tissue
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
FR2732604B1 (fr) * 1995-04-07 1997-06-06 Vacsyn Sa Derives et conjugues du mdp presentant une activite stimulatrice de la fonction hematopoietique et compositions les contenant
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JP2002529502A (ja) 1998-11-17 2002-09-10 スミスクライン・ビーチャム・コーポレイション 血小板減少症の治療法
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
HK1044334A1 (zh) 1999-02-01 2002-10-18 Cv治疗公司 依赖细胞周期蛋白的激酶2和IκB-α的嘌呤抑制剂
WO2000066112A1 (fr) 1999-05-03 2000-11-09 Smithkline Beecham Corporation Antagonistes du recepteur cxcr-4 et mimetiques de thrombopoietine
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
CN1110552C (zh) 1999-07-13 2003-06-04 中国人民解放军第二军医大学 一种体外扩增造血干细胞的新方法
AU770564B2 (en) 1999-09-10 2004-02-26 Smithkline Beecham Corporation Thrombopoietin mimetics
WO2001021180A1 (fr) 1999-09-24 2001-03-29 Smithkline Beecham Corporation Mimetiques de la thrombopoietine
EP1228051A1 (fr) 1999-11-05 2002-08-07 SmithKline Beecham Corporation Derives de semicarbazone et leur utilisation en tant que mimetiques de la thrombopoietine
ES2275567T3 (es) 1999-12-06 2007-06-16 Smithkline Beecham Corporation Mimeticos de4 trombopoietina.
ATE327242T1 (de) 1999-12-17 2006-06-15 Ariad Pharma Inc Neue purine
IL150594A0 (en) * 2000-01-07 2003-02-12 Ustav Ex Botan Adademie Ved Ce Purine derivatives, process for their preparation and use
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
AU7107301A (en) * 2000-07-18 2002-01-30 Nichimo Co. Ltd. Stem cell reinforcing material
JP2004520302A (ja) 2000-12-19 2004-07-08 スミスクライン・ビーチャム・コーポレイション トロンボポエチン模倣物
EP1370252A4 (fr) 2001-03-01 2006-04-05 Smithkline Beecham Corp Mimetiques de la thrombopoietine
EP1578722A4 (fr) * 2001-10-12 2006-09-06 Irm Llc Squelettes d'inhibiteurs de kinase et leurs methodes de preparation
DE60231328D1 (de) 2001-12-28 2009-04-09 Asubio Pharma Co Ltd Cofilin zur förderung der proliferation und/oder differenzierung hämatopoetischer stammzellen und/oder hämatopoetischer vorläuferzellen
WO2003103686A1 (fr) 2002-06-06 2003-12-18 Smithkline Beecham Corporation Mimetiques de la thrombopoietine
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
JP2004089068A (ja) * 2002-08-30 2004-03-25 Kobe University Ａｈ受容体リガンド特異的な遺伝子発現誘導因子及びその機能に基づく異種遺伝子誘導発現系の利用技術
AU2003297925A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Thrombopoietin mimetics
US20070161582A1 (en) * 2003-08-08 2007-07-12 Dusan Mijikovic Pharmaceutical compositions and methods for metabolic modulation
WO2005026164A1 (fr) * 2003-09-18 2005-03-24 Altana Pharma Ag Imidazo[4,5-c]pyridines a activite pharmacologique
WO2005063258A1 (fr) 2003-12-22 2005-07-14 Gilead Sciences, Inc. Conjugues de phosphonate inhibant la kinase
WO2005080377A1 (fr) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha Composé ayant une activité d'inhibition du tgf-∃ et composition pharmaceutique contenant celui-ci
US7622108B2 (en) * 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
MX2007002727A (es) * 2004-09-03 2008-03-04 Prometic Biosciences Inc Derivados de purinilo sustituidos con actividad inmunomoduladora y quimioprotectora, y su uso solos o con acidos grasos de longitud de cadena media o gliceridos.
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
KR20070058602A (ko) * 2004-09-30 2007-06-08 티보텍 파마슈티칼즈 리미티드 Ｈｃｖ 저해 바이-사이클릭 피리미딘
FR2876583B1 (fr) 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
US20080119510A1 (en) * 2004-12-09 2008-05-22 Altana Pharma Ag Substituted Imidazo [4,5-B] Pyridines As Inhibitors Of Gastric Acid Secretion
WO2006118914A2 (fr) * 2005-04-29 2006-11-09 Children's Medical Center Corporation Methodes d'augmentation de la proliferation de cardiomyocytes mammiferes adultes par inhibition de la map-kinase p38
MX2008000462A (es) 2005-07-14 2008-03-10 Irm Llc Compuestos heterotetraciclicos como mimeticos de tpo.
KR20080035700A (ko) 2005-08-15 2008-04-23 아이알엠 엘엘씨 Ｔｐｏ 모방체로서의 화합물 및 조성물
PT2322525E (pt) * 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
WO2007145227A1 (fr) 2006-06-14 2007-12-21 Chugai Seiyaku Kabushiki Kaisha Promoteur de la prolifération des cellules souches hématopoïétiques
US8372797B2 (en) * 2006-06-22 2013-02-12 Creative Medical Health, Inc. Treatment of erectile dysfunction by stem cell therapy
EP1889846A1 (fr) * 2006-07-13 2008-02-20 Novartis AG Dérivés de purine comme agonistes du recepteur A2a
WO2008028645A1 (fr) 2006-09-05 2008-03-13 Aplagen Gmbh Peptides se liant au récepteur de tpo
EP2617423A1 (fr) 2006-10-19 2013-07-24 Genzyme Corporation Dérivés de la purine pour le traitement de maladies kystiques
EP2094839B1 (fr) 2006-12-08 2020-02-05 University of Rochester Expansion de cellules souches hématopoïétiques
EP2144911A2 (fr) * 2007-03-28 2010-01-20 NeuroSearch AS Dérivés de purinyle et leur utilisation en tant que modulateurs des canaux potassiques
US8987280B2 (en) * 2008-01-30 2015-03-24 Genentech, Inc. Pyrazolopyrimidine PI3K inhibitor compounds and methods of use
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US9175266B2 (en) * 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity

Also Published As

Publication number Publication date
US9580426B2 (en) 2017-02-28
SI2350078T1 (sl) 2019-08-30
US20100183564A1 (en) 2010-07-22
US8927281B2 (en) 2015-01-06
BRPI0921799B8 (pt) 2021-05-25
CR20110192A (es) 2011-06-10
JP2012507554A (ja) 2012-03-29
CA2740589C (fr) 2017-11-21
CA3061937A1 (fr) 2010-05-27
CA2943540A1 (fr) 2010-05-27
PT2350078T (pt) 2019-07-19
TWI532486B (zh) 2016-05-11
RS59027B1 (sr) 2019-08-30
GEP20146053B (en) 2014-03-10
US20210187033A1 (en) 2021-06-24
MY155137A (en) 2015-09-15
KR20110075042A (ko) 2011-07-05
ES2948567T3 (es) 2023-09-14
NI201100083A (es) 2011-11-03
HUE044802T2 (hu) 2019-11-28
ECSP11011090A (es) 2011-09-30
CN102203096A (zh) 2011-09-28
CL2013001874A1 (es) 2014-04-04
SV2011003888A (es) 2011-07-05
AU2009317898B2 (en) 2013-07-11
EA201100663A1 (ru) 2011-12-30
IL212368A (en) 2015-02-26
MX347834B (es) 2016-10-07
CN102203096B (zh) 2014-09-17
JP5390626B2 (ja) 2014-01-15
HRP20191238T1 (hr) 2019-11-29
CO6410309A2 (es) 2012-03-30
WO2010059401A3 (fr) 2010-09-23
AR074063A1 (es) 2010-12-22
EP2350078B1 (fr) 2019-04-17
CL2009002010A1 (es) 2010-06-25
MX2011004593A (es) 2011-06-16
KR101434719B1 (ko) 2014-08-27
LT2350078T (lt) 2019-07-25
EA019872B1 (ru) 2014-06-30
EP3524604A1 (fr) 2019-08-14
BRPI0921799A2 (pt) 2016-01-12
TN2011000174A1 (en) 2012-12-17
PL2350078T3 (pl) 2019-09-30
US20140114070A1 (en) 2014-04-24
ES2736728T3 (es) 2020-01-07
IL212368A0 (en) 2011-06-30
CA2740589A1 (fr) 2010-05-27
JO3593B1 (ar) 2020-07-05
EP3524604B1 (fr) 2023-03-29
SMAP201100024A (it) 2011-07-11
CU20110096A7 (es) 2012-01-31
CU24495B1 (es) 2021-01-12
DK2350078T3 (da) 2019-07-15
PE20100362A1 (es) 2010-05-27
HN2011001195A (es) 2014-01-13
AU2009317898A1 (en) 2010-05-27
DOP2011000114A (es) 2017-09-29
EP2350078A2 (fr) 2011-08-03
TW201028153A (en) 2010-08-01
CY1121857T1 (el) 2020-07-31
SMP201100024B (it) 2012-03-05
CA2943540C (fr) 2020-10-27
NZ592435A (en) 2013-01-25
BRPI0921799B1 (pt) 2020-09-29
US20170239296A1 (en) 2017-08-24
WO2010059401A2 (fr) 2010-05-27

Similar Documents

Publication Publication Date Title
MA32828B1 (fr) Composes qui favorisent le developpement de cellules souches hematopoietiques
Doxiadis et al. Simpler and equitable allocation of kidneys from postmortem donors primarily based on full HLA-DR compatibility
Magatti et al. Human amnion mesenchyme harbors cells with allogeneic T-cell suppression and stimulation capabilities
Wang et al. A potential side effect of cyclosporin A: inhibition of CD4+ CD25+ regulatory T cells in mice
Guardiola et al. Outcome of 69 allogeneic stem cell transplantations for Fanconi anemia using HLA-matched unrelated donors: a study on behalf of the European Group for Blood and Marrow Transplantation
Haddad et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell–depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients
Poli et al. CD56bright natural killer (NK) cells: an important NK cell subset
Ozsahin et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation
Issa et al. Ex vivo–expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model
Edozie et al. Regulatory T-cell therapy in the induction of transplant tolerance: the issue of subpopulations
Kohler et al. Life after the thymus: CD31+ and CD31− human naive CD4+ T-cell subsets
Kalscheuer et al. Xenograft tolerance and immune function of human T cells developing in pig thymus xenografts
WO2018160768A8 (fr) Compositions et méthodes d'inhibition de protéines spécifiques d'une lignée
Düster et al. T cell‐derived IFN‐γ downregulates protective group 2 innate lymphoid cells in murine lupus erythematosus
Mathes et al. Tolerance to vascularized composite allografts in canine mixed hematopoietic chimeras
Vitale et al. Analysis of the activating receptors and cytolytic function of human natural killer cells undergoing in vivo differentiation after allogeneic bone marrow transplantation
Valdez‐Ortiz et al. Induction of suppressive allogeneic regulatory T cells via rabbit antithymocyte polyclonal globulin during homeostatic proliferation in rat kidney transplantation
Fehr et al. A CD8 T cell–intrinsic role for the calcineurin-NFAT pathway for tolerance induction in vivo
Pilat et al. Polyclonal recipient nTregs are superior to donor or third‐party Tregs in the induction of transplantation tolerance
Mathes et al. Stable mixed hematopoietic chimerism permits tolerance of vascularized composite allografts across a full major histocompatibility mismatch in swine
Stark et al. Meeting report: the sixth international sam strober workshop on clinical immune tolerance
Andreani et al. Mixed chimerism evolution is associated with T regulatory type 1 (Tr1) cells in a β-thalassemic patient after haploidentical haematopoietic stem cell transplantation
Kreijveld et al. KIR gene and KIR ligand analysis to predict graft rejection after renal transplantation
Hoerning et al. Peripherally circulating CD4+ FOXP3+ CXCR3+ T regulatory cells correlate with renal allograft function
Pilat et al. Therapeutic efficacy of polyclonal tregs does not require rapamycin in a low-dose irradiation bone marrow transplantation model